Aneurysmal subarachnoid hemorrhage (SAH) induces a potent inflammatory cascade that contributes to endothelial dysfunction, imbalance of vasoactive substances (excess endothelin, depletion of nitric oxide), and arterial vasospasm. This process results in delayed cerebral ischemia, a major cause of neurologic disability in those surviving the initial hemorrhage. The only therapy shown to be effective in improving neurologic outcomes after SAH is a calcium-channel antagonist, nimodipine (although it achieved this result without reducing vasospasm). A number of novel therapies have been explored to inhibit the development of vasospasm and reduce the burden of ischemia and cerebral infarction. Statins are promising candidates, as they block multiple aspects of the inflammatory pathway that contributes to ischemic brain injury. Early clinical trials have produced conflicting results, however, and the adoption of statins in clinical practice should await the results of larger, more definitive studies. Though endothelin-receptor antagonists showed promise in significantly reducing vasospasm in preliminary trials, their failure to improve clinical outcomes in phase 3 studies has been disappointing, highlighting the complex link between vasospasm and ischemia. Future directions in the quest to improve outcomes of patients with SAH may need to approach ischemia as a multifactorial process with inflammatory, vasoactive, and ionic/metabolic components.
Introduction
The rupture of an intracranial aneurysm is a devastating cerebrovascular event that results in subarachnoid hemorrhage (SAH). The acute release of blood into the subarachnoid space and rise in intracranial pressure initiates a cascade of events over the ensuing days that culminates in arterial vasospasm, seen in up to 70% of patients with aneurysmal SAH [1] , placing patients at risk for delayed cerebral ischemia (DCI). Ischemia, resulting in neurologic deficits in 20-30% of patients, as well as cerebral infarction, is the leading cause of morbidity in survivors of SAH [2] . Although the risk and distribution of arterial narrowing correlates with the volume and location of blood clot [3] , ischemia is not simply related to the presence of blood or even vasospasm alone [4, 5] .
Inflammation and endothelial dysfunction are increasingly being recognized as central to the pathophysiology of this complex and potentially devastating process ( Fig. 1) [6, 7•] . Aneurysmal rupture and subarachnoid blood activate the release of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α [8] [9] [10] . Neutrophils are attracted to the sites of cerebral inflammation, binding to vascular endothelium in a process mediated by molecules such as intercellular adhesion molecule 1 (ICAM-1) and the selectins [11, 12] . Activated leukocytes within the subarachnoid space contribute to vasospasm by promoting production of endothelin-1, a potent vasoconstrictor, depleting nitric oxide (NO), and producing reactive oxygen species [13] . Free radicals enhance lipid peroxidation and oxidation of bilirubin, both of which can injure smooth muscle cells [14] . This inflammatory mechanism for vasospasm is evidenced by infiltrates of inflammatory cells seen in walls of affected intracranial vessels [15] , and the observation that polymorphisms in the eNOS (endothelial nitric oxide synthase) gene affects susceptibility to vasospasm [16] .
Experimental studies support a causative role for inflammation, demonstrating that arterial narrowing is reduced by inhibiting various steps of the inflammatory pathway [17, 18] . Studies of patients with SAH have shown a correlation between inflammatory markers and vasospasm/DCI [19] [20] [21] . The recognition of the role that inflammation may play in genesis of vasospasm and DCI has led to considerable interest in drugs that block these pathways as a means of ameliorating vasospasm and preventing morbidity from ischemia after SAH.
Treatment Diet and lifestyle
& Smoking is a well-established risk factor for SAH and increases the risk for aneurysmal rupture in those with unruptured aneurysms [22, 23, Class II] . This risk appears to be eliminated within a few years of smoking cessation [22, Class III] . Smoking is also a risk factor for the development of vasospasm and cerebral infarcts after SAH [24-27, Class II] . There has been concern about the use of nicotine replacement therapy (NRT) in patients with acute SAH, given the vasoactive properties of nicotine and the potential to worsen endothelial damage [28] . However, a recent retrospective study found that NRT appeared safe in SAH patients, with no excess incidence of DCI; it may even be associated with better outcomes, although with a higher incidence of delirium and seizures [29, Class III] . Corticosteroids possess anti-inflammatory properties including the ability to inhibit cyclooxygenase, lipid peroxidation, and free radical production [32] . Three randomized trials of corticosteroids in SAH were analyzed in a Cochrane review [33] . Only one tested a glucocorticoid (hydrocortisone), which was started in those already exhibiting deficits attributed to DCI [34, Class II] . Steroid therapy did not improve outcomes in these patients but Figure 1 . Pathophysiology of secondary brain injury after subarachnoid hemorrhage. NO nitric oxide, NOS nitric oxide synthase, eNOS endothelial NOS, nNOS neuronal NOS.
Pharmacologic treatment
was associated with an increase in adverse events, mainly related to steroidinduced hyperglycemia. Hydrocortisone does appear to prevent natriuresis and hyponatremia, a common problem in patients with SAH, as demonstrated a single small, randomized trial [35, Class II] . A preliminary nonrandomized study evaluated methylprednisolone compared with matched controls in patients at high risk for vasospasm and found improved outcomes in treated patients [36] . Recently a larger randomized trial in 95 patients evaluated high-dose methylprednisolone given early after aneurysmal rupture [37] . Treatment did not reduce the incidence of delayed ischemic deficits attributable to vasospasm or cerebral infarction, although an SAH-associated spike in C-reactive protein levels was attenuated compared with controls. However, 1-year functional outcome tended to be better in steroid-treated patients, with 69% achieving a good outcome (defined as a modified Rankin scale of 0-2) versus 54% with placebo (P=0.13, Class II). Further confirmation of this benefit will be required before steroids can be adopted as standard treatment for SAH.
Free radical scavengers
Tirilazad is a synthetic non-glucocorticoid 17-aminosteroid that inhibits lipid peroxidation and injury to endothelial and smooth muscle cells by scavenging free radicals and stabilizing cell membranes [38] . It has been studied in five randomized trials of 3,821 patients with SAH [39] . Although fewer patients developed symptomatic vasospasm or DCI (OR, 0.80; 95% CI, 0.69-0.93), no improvement in death or poor outcome (including cerebral infarction) was seen in a recent meta-analysis [39, Class I].
Edaravone, another free radical scavenger, has recently been evaluated as a means of inhibiting the development of vasospasm after SAH. A study of 91 patients randomized to treatment or placebo found a trend to reduction of ischemic deficits (10% vs 21%, P=0.12) [40, Class II]. Cerebral infarction was reduced from 21% to 4% (P=0.01). Favorable outcome occurred in 92% of treated patients and 83% of controls (P= 0.09). Larger randomized studies are needed to verify these promising but preliminary findings.
Nonsteroidal antiinflammatory drugs
Acetylsalicylic acid (ASA) is an antiinflammatory as well as an antiplatelet agent; both of these properties may be beneficial in preventing ischemia after SAH. Based on a meta-analysis of preliminary studies suggesting reduction in ischemic deficits with ASA treatment, a larger randomized, placebo-controlled trial (using 100 mg ASA rectally) was performed in 161 SAH patients [41, Class I]. ASA tended to increase the incidence of ischemic deficits with no change in the number of infarcts or neurologic outcome. At this point, treatment with ASA cannot be recommended in SAH.
No human studies of ibuprofen have been performed, but experimental studies have found a reduction in vasospasm possibly mediated through the drug's ability to inhibit leukocyte-endothelial interactions [42, 43] .
Statins HMG-CoA reductase inhibitors ("statins") exhibit pleiotropic actions that may be beneficial in attenuating some of the inflammatory and vasoactive disturbances underlying vasospasm and DCI. They restore eNOS activity, increase NO levels [44, 45] , and block the activation and migration of inflammatory leukocytes [46, 47] . Statins are able to stabilize endothelial and autoregulatory function, may possess antiplatelet and antithrombotic properties, prevent neuronal apoptosis, and scavenge free radicals (Table 1) [48, 49] . Experimental evidence has supported their ability (albeit when given at much higher doses than used in humans and either prior to or early after SAH) to attenuate development of vasospasm in animal models, inhibiting inflammatory infiltration of vessel walls [45, 47] .
Four small, randomized controlled trials enrolling a total of 190 patients have now been published evaluating the use of simvastatin and pravastatin in patients with SAH (Table 2) ; two additional trials have been published only in abstract form [50] [51] [52] [53] . These trials have assessed whether early statin treatment can reduce vasospasm and DCI, and improve outcomes. A metaanalysis of these published trials (using a random effects model) found no reduction in vasospasm (defined by transcranial Doppler [TCD] criteria), a nonsignificant trend to reduction in ischemic neurologic deficits (OR, 0.57; 95% CI, 0.29-1.13) and mortality (OR, 0.37; 95% CI, 0.13-1.10) [54•, Class I]. Poor neurologic outcome was unaffected by statin treatment.
Another recent systematic review used a fixed-effects model (which may be inappropriate when combining small heterogeneous studies) and found that statins appeared to reduce incidence of delayed ischemic deficits and mortality [55] . AHA guidelines do not recommend statins for patients with SAH, pending results of a larger, multicenter randomized trial with 40 mg of simvastatin that is aiming to enroll 800 SAH patients in the United Kingdom (ISRCTN75948817; also ClinicalTrials. gov Identifier NCT00731627) [56] .
Standard dosage Simvastatin 40-80 mg daily or pravastatin 40 mg daily. Not approved for SAH.
Contraindications Avoid with liver disease (including elevated transaminases) or pregnancy; caution if muscle disease (or elevated creatine kinase, CK). Use of simvastatin 80 mg was recently discouraged by an FDA advisory, based on a higher risk of myopathy and rhabdomyolysis in clinical trials and postmarketing surveillance. My- opathy (with CK 10×ULN) was 45 times more common with 80 mg of simvastatin than with 20 mg [57] . The incidence of rhabdomyolysis was 0.4% (approximated at 2 per 1,000 in the first year of treatment). If the higher dose is to be used, close monitoring of CK is recommended. Though the trials of statins in SAH were underpowered to detect rare adverse effects, no clear excess of myopathy was noted in any of the available studies.
Main drug interactions
Simvastatin is metabolized by the cytochrome P450 system, and levels will be increased by drugs that inhibit enzymatic activity of this system (e.g., protease inhibitors, erythromycin, verapamil, diltiazem, amiodarone, digoxin, cyclosporine, azole antifungals, and warfarin). Pravastatin is not metabolized through this pathway and its use should avoid such interactions. The combination of statins with drugs like niacin or fibrates may increase the risk of rhabdomyolysis or liver failure.
Main side effects Elevation in transaminases and/or CK, muscle pain and/or myopathy.
Special points For patients using statins prior to SAH, abrupt withdrawal after admission may be associated with elevated risk of vasospasm [58, 59] . Statin withdrawal has been linked to acutely worsening inflammation, suppression of eNOS, and a rise in production of free radicals. Statins should be continued in any patient taking them prior to admission.
Cost Relatively inexpensive and cost-effective if able to prevent disability from DCI.
Endothelin antagonists
Endothelin, a powerful vasoconstrictor, has been implicated in the pathophysiology of cerebral vasospasm. Endothelin levels are elevated in the CSF of patients with SAH [60] , with a profile that mirrors the time course of vasospasm [61] . Activated leukocytes contribute to endothelin production [62] , again tying inflammation into the vasoactive theory of DCI. Preliminary clinical studies found that clazosentan, an endothelin-1 receptor antagonist, significantly reduced angiographic vasospasm in a dose-dependent manner [1] . A recent phase 3 trial tested clazosentan in SAH patients who had undergone surgical clipping of a ruptured aneurysm [63, Class I] . No improvement in the primary endpoint (mortality, vasospasm-related infarction, delayed ischemic deficits due to vasospasm, and rescue therapy for vasospasm) was seen (21% vs 25%, P=0.1), and poor functional outcome actually was more common in the clazosentan-treated patients. This result may have been due to an increased risk of extracerebral adverse events, including hypotension, anemia, and pulmonary edema. The results of the CONSCIOUS-3 study in patients treated with endovascular coiling have not yet been reported [64] . The use of clazosentan is neither approved nor recommended in SAH.
Erythropoietin
Erythropoietin (EPO) not only may augment hemoglobin production but also possesses a variety of neuroprotective and immunomodulatory properties. It may interact with endothelial EPO receptors to augment eNOS expression and NO production [65] . It exhibited promise in experimental studies of ischemic stroke [66] , but a recently published clinical trial found a significantly higher mortality rate in treated patients [67] . A small, phase 2 proof-of-concept study was performed administering three doses of EPO acutely after SAH [68, Class II] . This study found no change in the overall rate of vasospasm, but the severity of vasospasm (using TCD criteria) was reduced, and ischemic deficits were less frequent. Phase 3 studies will be required to confirm the role of EPO in SAH and exclude risk as demonstrated in ischemic stroke trials.
Interventional procedures
& Conventional catheter angiography remains the gold standard for diagnosing cerebral vasospasm. Furthermore, angiography not only allows accurate diagnosis of vasospasm but also provides opportunity for therapeutic interventions to reduce arterial narrowing. Angioplasty Standard procedure A balloon is inflated after a microcatheter is passed across the segment of arterial narrowing, producing a sustained increase in luminal diameter. Clinical improvement may be seen in at least 60% of patients. No controlled studies have been performed to demonstrate better outcomes.
Contraindications Intracranial aneurysm in the same vessel segment inability to access the affected segment (common for A1 or other distal vessels).
Complications Vessel perforation or rupture (often fatal), dissection, and hemorrhage from an unsecured aneurysm [69] .
Special points Angioplasty is a relatively durable treatment option, with most segments not requiring retreatment (i.e., recurrent vasospasm is rare). Early treatment (shortly after onset of deficits, rather than waiting for hours to days for failure of medical therapies) may be better to prevent permanent sequelae [70] . Prophylactic angioplasty did not reduce delayed ischemic deficits or TCD-defined vasospasm in high-risk patients, who had similar functional outcomes but a number of procedure-related deaths [71] Cost Expensive, requires special expertise (only available in certain centers).
Intraarterial vasodilators
Standard procedure A vasodilator (such as nicardipine, verapamil, magnesium, or milrinone) is infused through an intracranial microcatheter into the affected vessel. This allows treatment of smaller, more distal arteries, which may not be accessible to angioplasty.
Contraindications Inability to pass microcatheter.
Complications The use of papaverine has largely been abandoned with the advent of safer options and recognition of various complications including raised intracranial pressure [72] , seizures [73] , and paradoxic worsening of vasospasm [74] .
Special points The dilatory response is more transient than seen with angioplasty, and treated vessel segments often require retreatment for recurrent vasospasm.
Cost Expensive, requires special expertise.
Surgery
& Definitive aneurysm treatment is essential to prevent rebleeding, which carries very high mortality. Surgical clipping or endovascular coiling are both options. Once the ruptured aneurysm has been secured, it is also safer to initiate hemodynamic therapies (such as induced hypertension) if ischemic deficits develop.
Emerging therapies
& Cortical spreading depression (CSD) describes a wave of neuronal depolarization that propagates across the cerebral cortex; it is frequently recorded in patients suffering from ischemia after SAH and may be associated with microvascular spasm and worsening tissue hypoxia [75] . Endothelin, ionic/membrane alterations, and oxidative stress appear to contribute to CSD. Therapies aimed at mitigating this potentially harmful electrical phenomenon may prevent further neuronal injury. Ketamine, a NMDA-receptor antagonist, has been proposed, but studies in SAH are lacking.
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